Clinical trials: Tacrolimus
Systemic Lupus Erythematosus
Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
The purpose of this study is to initially access the safety and effectivity of RC18 combined with standard treatment and Placebo combined with standard therapy in subjects with Moderate to severe SLE.
- Trial name
- NCT04082416
- Testing
- RC18 160 mg plus standard therapy
- Where
- China
- Volunteers
- 335 people
- Sponsor
- RemeGen Co., Ltd.
Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
This phase Ib trial studies the side effects of combination chemotherapy and donor stem cell transplant followed by ixazomib citrate maintenance therapy in treating patients with multiple myeloma that has returned after a period…
- Trial name
- NCT02504359
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- OHSU Knight Cancer Institute
MDS, Leukemias
Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy
The purpose of this study is to see if giving high dose chemotherapy and total body irradiation before and repeating high dose chemotherapy after a bone marrow transplant could reduce the incidence of graft rejection and disease…
- Conditions
- MDS, Leukemias, Lymphomas
- Trial name
- NCT00796562
- Testing
- Busulfan, Cyclophosphamide, Total body irradiation
- Where
- 2 sites in United States
- Volunteers
- 107 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
BK Viremia, BK Nephropathy
Using mTOR Inhibitors in the Prevention of BK Nephropathy
BK virus infections after kidney transplant are increasing and can result in damage to the transplanted kidney. Currently, the universally accepted treatment is to decrease the strength of the antirejection medications but it is…
- Trial name
- NCT01649609
- Testing
- Tacrolimus, Mycophenolate acid, Sirolimus
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Columbia University
Myeloproliferative Disorders, Leukemia
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00827099
- Testing
- anti-thymocyte globulin, fludarabine phosphate, Melphalan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northside Hospital, Inc.
Polycystic Liver Disease
Polycystic Liver Disease in Kidney Transplant
The purpose of this study is to see if one kind of immunosuppressive drug has better effects for the patient's polycystic liver disease than another type.
- Trial name
- NCT00934791
- Testing
- Tacrolimus, Sirolimus, Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Kidney Transplant; Complications, Drug Interaction Food
Drug Interaction With Envarsus XR and Grapefruit Juice
Transplant patients must take lifelong immunosuppression in order to prevent rejection of their organ. Tacrolimus is the most widely used immnosuppressive agent.
- Trial name
- NCT03916380
- Testing
- Grapefruit Juice
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Shirley M. Tsunoda
Transplant Recipient (Kidney)
Immune Monitoring-Guided Individualized Tacrolimus Therapy in Renal Transplant Recipients: An Observational Study and PK/PD Modeling
This study aims to resolve the clinical limitation that therapeutic drug monitoring (TDM) alone cannot accurately reflect the net immune status after kidney transplantation.
- Trial name
- NCT07815938
- Testing
- No interventional treatment, only observational data collection without clinical drug adjustment
- Volunteers
- 50 people
- Sponsor
- Zhongnan Hospital
Primary Membranous Nephropathy
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).
- Trial name
- MAJESTY (NCT04629248)
- Testing
- Obinutuzumab, Tacrolimus, Methylprednisolone
- Where
- 50 sites in United States, Argentina and 9 more
- Volunteers
- 142 people
- Sponsor
- Hoffmann-La Roche
Evidence of Liver Transplantation
A Pilot Trial of Pediatric Liver Transplantation Without Steroids
Objective: The overall objective is to investigate whether a steroid free immunosuppressive regimen is as safe and effective as a steroid containing regimen following pediatric liver transplantation and whether it promotes…
- Trial name
- NCT00694408
- Testing
- methyl prednisolone, hydrocortisone, prednisolone, No steroids
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Birmingham Women's and Children's NHS Foundation Trust
Kidney Transplant, Immunosuppression
Prospective Cohort of Kidney Transplanted Patients Receiving an Extended Releasing Tacrolimus-Everolimus Association
The tacrolimus-Everolimus association is used as an immunospressive treatment after a kidney transplant. It combined immunosupressive properties of both products and reduce the nephrotoxicity of tacrolimus by lowering the dosage.
- Trial name
- NCT03228576
- Testing
- Extended release Tacrolimus-Everolimus association
- Where
- 9 sites in France
- Volunteers
- 16 people
- Sponsor
- Poitiers University Hospital
Patients With Type 1 Diabetes
Allogeneic Islet Transplantation for the Treatment of Type 1 Diabetes
It is a multicentre, sequential, phase II clinical trial, aiming at evaluating the allogeneic islet transplantation for the treatment of type 1 diabetes.
- Trial name
- GRIIF (NCT01974674)
- Testing
- Allogeneic transplantation of intrahepatic islet
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Transplantation
Model-based Medication Dosing Assist for Tacrolimus in Kidney Transplantation
The daily dosing of tacrolimus, the most important immunosuppressant used after kidney transplantation, is a rather complex process in which many factors can have an influence in each individual in a unique way and variable over…
- Trial name
- MIPDTac (NCT07030660)
- Testing
- Model-Informed Precision Dosing (MIPD)
- Where
- Belgium
- Volunteers
- 357 people
- Sponsor
- KU Leuven
Graft Rejection, Kidney Failure
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
The primary purpose of this study is to determine whether converting from calcineurin inhibitor (CNI) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal…
- Trial name
- NCT00369382
- Testing
- cyclosporine or tacrolimus, sirolimus
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 121 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Dermatitis, Atopic
A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis
The purpose of the study is to determine the impact of topical corticosteroids on the safety and effectiveness of Protopic Ointment in the short-term treatment of moderate to severe Atopic Dermatitis and to compare the safety and…
- Trial name
- NCT00106496
- Testing
- Protopic, Corticosteroid
- Where
- 24 sites in United States
- Volunteers
- 410 people
- Sponsor
- Astellas Pharma Inc
Immunosuppression
Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients
This was a study to compare less intense immunosuppression with a more traditional approach. The hypothesis was that less immunosuppression will provide similar protection against rejection than typical 2-3 drug therapy.
- Trial name
- TICTAC (NCT00299221)
- Testing
- Tacrolimus, combination therapy
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Newark Beth Israel Medical Center
Systemic Lupus Erythematosus
Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)
The purpose of this study is to initially access the safety and effectivity of RC18 combined with standard treatment and Placebo combined with standard therapy in subjects with Moderate to severe SLE, Besides ,to provide dose…
- Trial name
- NCT02885610
- Testing
- RC18 80 mg plus standard therapy, RC18 160 mg plus standard therapy, RC18 240 mg plus standard therapy
- Where
- China
- Volunteers
- 249 people
- Sponsor
- RemeGen Co., Ltd.
Kidney Transplantation
Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal
Current therapy to prevent organ rejection relies on the use of calcineurin inhibitors either cyclosporine or tacrolimus. Although these agents have been very successful in preventing early acute rejection, this success has not…
- Trial name
- NCT00896012
- Testing
- Kidney Biopsy, Rapamune (sirolimus/rapamycin), Tacrolimus
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University at Buffalo
Multiple Myeloma, Plasma Cell Neoplasm
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells.
- Trial name
- NCT00028600
- Testing
- filgrastim, CD34+ cells, cyclophosphamide
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Renal Transplantation
Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
To compare renal allograft rejection rates during the first year among high-immunological risk recipients between patients who received either ATG or the anti-IL2R mAb daclizumab.
- Trial name
- TAXI (NCT00682292)
- Testing
- Thymoglobulin (ATG), Daclizumab
- Where
- France
- Volunteers
- 227 people
- Sponsor
- University Hospital, Lille